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Abstract
Magnetic nanoparticles (MNPs) play a vital role for improved imaging applications. Recently, a
number of studies demonstrate MNPs can be applied for targeted delivery, sustained release of
therapeutics, and hyperthermia. Based on stable particle size and shape, biocompatibility, and
inherent contrast enhancement characteristics, MNPs have been encouraged for pre-clinical studies
and human use. As a theranostic platform development, MNPs need to balance both delivery and
imaging aspects. Thus, this review provides significant insight and advances in the theranostic role
of MNPs through the documentation of unique magnetic nanoparticles used in prostate cancer,
their interaction with prostate cancer cells, in vivo fate, targeting, and biodistribution. Specific and
custom-made applications of various novel nanoformulations in prostate cancer are discussed.
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Introduction
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Prostate cancer is the most frequently diagnosed malignancy in men [1]. According to the
World Health Organization (GLOBOCAN 2012), 1.1 million cases of prostate cancer were
recorded in 2012, accounting for 15% of all cancer cases in men [2,3]. France (~227 cases
per 100,000) and Norway (~129 cases per 100,000) have the highest rates of prostate cancer,
respectively, while the United States has the 14th highest prevalence rate with approximately
98 cases per 100,000. Although cancer death rates are declining, the management of the
disease remains very expensive and painful. Therefore, it is highly crucial to ascertain the
progress of the disease and identify better diagnosis, imaging and treatment modalities.
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Nanotechnology has demonstrated to be one of the most prominent developments in
materials sciences, pharmaceutical, and medicine. This is supported by more than 65,000
reported studies that utilize/reference nanotechnology on PubMed [4]. Nanotechnology is
generally referenced as a material science dedicated to the branches of science: engineering
and medicine. The functional unit of nanotechnology, or nanoparticles, is frequently
characterized by its size, measured on the nanometer scale. According to the National
Institute of Health (Nanotechnology Safety and Health Program at the Division of
Occupational Health and Safety), nanoparticles are defined as nanoscale materials whose
dimensions are less than 100 nm. In fact, the smaller size and high surface to volume ratio
are what provide nanoparticles with their unique physicochemical properties. Over the years,
different versions of nanotechnology, from natural resources to various synthetic routes,
have been generated based on the specific demand. Poly(lactic-co-glycolic acid) (PLGA)
and poly(ε-caprolactone) (PCL) are the most commonly used biodegradable and
biocompatible polymers in a number of medical applications.

Author Manuscript

Magnetic nanoparticles (MNPs) (Fig. 1) are a class of nanoparticles extensively used from
basic biomaterial research to pre-clinical and clinical trials due to the ultra-small nanometer
size, inherent magnetic resonance imaging (MRI) characteristics, superior biocompatibility,
flexible surface chemistry, and lack of systemic toxicities. These unique properties are what
gained the interest of scientists for evaluating the nanocarrier potential of MNPs in various
therapeutic aspects for different types of cancers, including prostate cancer. In addition,
magnetic nanoparticle degradation results in the production of iron ions, which exist
abundantly in the human body, further indicating the safety perspective. As a result, among
all types of magnetic nanoparticles, iron oxide based magnetic nanoparticles (Feridex I.V.®,
Feraheme®, Endorem®, Lumiren®, and Gastromark®) have been approved for human
clinical studies due to an extended safety profile and greater serum bioavailability (up to 30
hrs).
The main focus of our laboratory is dedicated to the fabrication and characterization of
magnetic nanoparticles followed by testing their drug/biomacromolecular compositions in
biologically and clinically relevant in vitro and in vivo cancer model systems [5–10]. As part
of our continuous research efforts, we aim to focus on the role of magnetic nanoparticles in
prostate cancer therapeutics. Therefore, this review is focused on demonstrating the
application of magnetic nanoparticles in the treatment, diagnosis, and targeting of prostate
cancer.

Magnetic Nanoparticles
Author Manuscript

Magnetic nanoparticles are a class of nanoparticles that can be applied to a wide number of
biomedical applications, such as drug delivery, imaging, diagnosis, biosensing,
bioseparation, targeting, and so on. A number of research/review articles have discussed the
development of nanoparticles in biomedical applications [11–14]. Among these
nanoparticles, superparamagnetic iron oxide nanoparticles (SPIONs) are not only approved
by the Food and Drug Administration (FDA) but are also widely used as contrast agents for
bowel, liver, and spleen imaging due to inherent biocompatibility and unique magnetic
characteristics. These formulations are generally synthesized through the co-precipitation
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approach in the presence of dextran polymer or a suitable stabilizing agent. However, this
approach leads to broad particle size distribution and low crystallinity. Non-hydrolytic
methods are used to produce high crystalline iron oxide nanoparticles with uniform size
distribution. Since this review’s focus is to delineate the application of magnetic
nanoparticles in prostate cancer, we have not considered the extensive preparative synthetic
procedures of magnetic nanoparticles, but this information can be found elsewhere [11–14].
Therefore, in this section, we will focus more on the creation of stable magnetic nanoparticle
composition (regulating size and shape of magnetic nanoparticles) that is responsible for
absorption, distribution, metabolism, and excretion (ADME). All these four criteria can
influence the level of exposure of magnetic nanoparticles to the tissues and thus the overall
activity of formulation.

Author Manuscript

Poly(ethylene glycol) or Pluronic® polymers are considered to be prime stabilizers for most
magnetic nanoparticles, due to enhanced circulation, minimized RES recognition, and
improved targeting of tumors by the enhanced permeation and retention (EPR) effect
[11,15]. Additionally, polymers such as PVA [16,17], PVP [18], starch [19], and chitosan
[20] have been successfully employed for this purpose. PLGA, PCL and their iron oxide
nanoparticle-based combinations have been widely explored as cancer drug delivery systems
[21–23]. Dextran is a universal stabilizer and approved FDA formulation of magnetic
nanoparticle for imaging applications. Many dextran-based formulations are highly
employed in proof-of-concept to clinic.

Author Manuscript

Albumin is another versatile coating for generating stable magnetic nanoparticle formulation
as a delivery carrier [24]. Similarly, dendrimer [25,26], polymersomes [27,28] and Pluronic®
polymers [5,7,27,29] are suitable for stabilization. Albumin is another commonly used and
clinically relevant stabilizing agent seen in various drug nanoparticle or drug formulations.
In a single step, magnetic nanoparticles decorated by albumin, which is cross-linked using
glutaraldehyde, were suitable for providing a uniform nanoparticle system for prostate
cancer [24,30]. Similarly, liposome [15,31,32], hybrid [33], and dual/multilayer can serve as
layers for stable nanoformulations. Stimuli responsive polymer coating on magnetic
nanoparticles can also induce controlled drug release characteristics [34,35]. In addition to
the conventional coating approach, nanohybrid materials with a magnetic core and gold
coating are very helpful in maintaining inherent characteristics of the iron core [36]. Table 1
demonstrates the critical role of nanoparticle surface coating in drug delivery application.

Delivery of therapeutics to prostate cancer
Author Manuscript

Upon diagnosis of prostate cancer, treatment options available are surgery, cryotherapy,
radiation therapy, hormone therapy, vaccination and bone-directed treatment, depending on
the stage of disease. These therapies are all moderately successful for the treatment of
prostate cancer. Patients diagnosed with localized prostate cancer may not only experience
therapy relapse, but also carry the major risk of developing advanced stage or androgenindependent prostate cancer. At this stage, chemotherapy is one of the most widely used
treatment modalities. However, most often, therapeutic efficacy of drugs is limited due to
lack of specificity, dose limiting systemic toxicity, and emergence of drug resistance in
tumors. This suggests that there is an urgent need for developing novel strategies with
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improved and selective targeting of agents, which can minimize systemic toxicity and
maximize therapeutic benefit. Therefore, delivery of therapeutics (drugs, peptides, proteins
or nucleic acids) with the construction of nanocarriers (magnetic nanoparticles) is a highly
feasible approach for prostate cancer treatment. A number of magnetic nanocarriers for this
application are presented in Table 1.
Paclitaxel is a commonly used chemotherapeutic agent for a wide variety of cancers. This
drug can be immobilized in the shell of poly[aniline-co-sodium-N-(1-one-butyric acid)
aniline] on MNP’s core, which can promote cytotoxic potential in PC3 and CWR22R human
prostate cancer cells over free paclitaxel drug [39]. Similarly, PEGylated magnetic
nanoparticle micelles with paclitaxel were able to improve paclitaxel potency against C4-2
cells derived xenograft tumors in athymic nude mice [38].

Author Manuscript

Docetaxel (Dtxl, Taxotere®) is another FDA-approved chemotherapeutic agent for prostate
cancer; however, its adverse toxic side effects significantly diminish its clinical use. A
magnetic nanoparticle formulation can enhance the delivery and efficacy of docetaxel in
prostate tumors [tested in prostate cancer cells (LNCaP, DU 145, and PC3)]. Such enhanced
cytotoxic effects of docetaxel-magnetic nanoparticle formulation were obtained via
suppression of nuclear transcription factor-κB (NF-κB) expression and increased apoptosis
induction [44]. Our recent investigation further proved that docetaxel was effectively
delivered to prostate cancer cells and tumor tissues with a specific construction of βcyclodextrin and Pluronic® polymer layers [9]. Similarly, improved anticancer activity of
docetaxel was achieved with a magnetic nanoparticle formulation decorated with polymer
vesicle layers [23]. This formulation showed a diameter of about 147 nm and exhibited
enhanced cellular uptake ability and antiproliferative activity in PC3 prostate cancer cells.

Author Manuscript

Mitoxantrone is another clinically approved drug for prostate cancer treatment. The
cytotoxic potency of this agent can be increased by using mitoxantrone loaded in composite
magnetic nanoparticles (an average size of 20 nm). This was confirmed by enhanced
cleavage in Poly(ADP-ribose) polymerase (PARP) protein and activation of caspase 3 in DU
145 cells upon treatment with mitoxantrone-loaded magnetic nanoparticles [45].
Mitoxantrone-iron oxide nanoparticles aid in increasing mitoxantrone concentration in
tumor tissue compared to mitoxantrone alone [46].

Author Manuscript

Moreover, magnetic nanoparticles often indicated increased efficacy of therapeutic agents
due to improved cellular uptake and targeted delivery, thus exhibiting selective toxicity
against prostate cancer cells. Therefore, magnetic nanoparticles represent a promising carrier
for many other anticancer drug molecules such as 5-fluorouracil (5-FU) [22], doxorubicin
(DOX) [37], flutamide (antagonist of the androgen receptor) [47], bicalutamide
(antiandrogen) [42], and zoledronate (antiosteoclastic properties) [43]. In addition, lipid
based magnetic nanoparticles are proposed extensively due to their drug depositing
efficiency in hydrophobic layers and convenience to synthesize using seed-growth methods
[15,48].
Stimuli-responsive polymer coatings can provide additional features to nanoparticle
formulations. For example, magnetodendrimers containing hydroxyl- or amino-end surface
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functional groups allow second generation nanocarriers to deliver drugs to prostate cancer
cells [25]. The advantage of this system is due to higher release of loaded drug at pH 5.8
(mimicking tumor environment) than at pH 7.4 (normal physiological condition). For
example, G1-NH2: 69% vs. 39%; G2-NH2: 49% vs. 33%; G1-OH: 92% vs. 46%; and G2OH: 74% vs. 41%, at pH 5.8 and pH 7.4, respectively. Such pH sensitivity arose due to the
presence of different amino groups in the inner layers of dendrimers. The higher drug
release phenomenon at low pH could be attributed to electrostatic repulsion between the
positive charges of ammonium ions. Due to hypoxia, pH of the tumors tends to be less than
7.4 at which stimuli-responsive magnetic nanoparticle can release high payload, thus helps
for successful treatment. A thermosensitive poly(N-isopropylacrylamide-co-acrylamide-coallylamine) coating on magnetic nanoparticles can release doxorubicin significantly at 41°C
compared to 37°C [35]. Another dual responsive polymer, poly(N-isopropylacrylamide-coacrylamide-co-chitosan) coating also offers an improved drug release characteristic (40°C:
~78%, 37°C:~33% and at pH 6: ~55%, pH 7.4: ~ 28%) [34].

Author Manuscript

Delivery of RNA therapeutics remains critical for many biomedical implications in
medicine. Among many transfecting agents, magnetic nanovector-based transfection is
under considerable attention. Magnetofection enhances cellular uptake of nanoparticles in
prostate cancer cells or tumor models under a magnetic field [49]. Absorption of
polyethyleneimine (PEI) on magnetic nanoparticles not only decreases PEI-associated
toxicity, but also enhances nucleic acid uptake by PC3 and DU 145 cancer cells [50].
Superparamagnetic nanoparticles with cationic lipids exhibit superior transfection efficiency
in PC3 prostate cancer cell lines [51]. Under gradient magnetic field, the transfection
efficiency is further increased by ~21% and 42% compared to liposomal magnetofection and
lipofection. More importantly, magnetic guided transfection is indeed less cytotoxic than
that under a permanent magnetic field and lipofection. Redox-sensitive polymer (thiol-linked
polyethyleneimine)-based iron oxide nanoparticle formulations are efficient magnetofection
agents of plasmid DNA [52]. Similarly, poly-arginine/PEG layered iron oxide nanoparticle
nanovector showed less toxicity and promoted SiRNA gene silencing in TC2/GFP(+)
(mimicking human prostate cancer) cells over polylysine and polyethyleneimine-coated
formulations [53]. Such an efficient transfection approach is feasible due to the cell
transcytosis intracellular trafficking pathway. It is also possible to extend the use of magnetic
nanoparticles for in vivo and in vitro transfection of antisense oligodeoxynucleotides,
plasmids, siRNA and shRNA [54-56].

Magnetic nanoparticles for targeted delivery
Author Manuscript

Clinical management of prostate cancer is often difficult due to the lack of specific and
targeted therapeutic intervention. Earlier approaches involved the use of anionic
glycosaminoglycan (dermatan sulfate) coated magnetic nanoparticles (enriched
oligosaccharide sequences that confers high heparin cofactor II binding), which target the
upregulated transport activities of neovascular endothelium [37]. This correlates with higher
cellular and tumor uptake in prostate R3327 AT1 rat tumors. Another magnetic nanoparticle
formulation with chlorotoxin peptide exhibits substantial targeting and accumulation in
cancer cells and inhibits invasiveness of cells (98%) [57]. The intercalation of doxorubicin in
the CG-rich duplex of prostate specific membrane antigen (PSMA) aptamer and in polymer
Drug Discov Today. Author manuscript; available in PMC 2018 August 01.
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layer exhibited a selective delivery and efficacy in the LNCaP xenograft mouse model [58].
Administration of this targeted drug nanoformulation was able to reduce tumor volume by
approximately 54% compared to the control group. A liposomal formulation consisting of
CdSe quantum dot decorated with phospholipid bilayer and iron oxide core particles, PEG
derivative and cRGDyk peptide showed good specificity against bone metastasized prostate
tumors [59].

Author Manuscript

Many other magnetic nanoparticle formulations are able to target prostate cancer cells and
tumors by targeting folate receptors [60], Mucin 1 [61,62]; urokinase plasminogen activator
(uPAR) [63]; gastric-releasing peptide receptors (GRPR) [64]; secreted protein, acidic and
rich in cysteine (SPARC) [65]; luteinizing hormone–releasing hormone (LHRH) [66]; heat
shock protein (HSP) [67]; prostate stem cell antigen (PSCA) [41]; and prostate cancerspecific R11 peptides [34]. The PLGA magnetic NPs formulation with cell penetrating
peptide-R11 and radio-sensitizer 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one
(NU7441) allows prostate cancer-specific targeting and sustained delivery over 3 weeks in
PC3 cells [40]. However, PSMA targeting using magnetic nanoparticles [38,58,68] is a
widely used approach for prostate cancer since almost all prostate tumors express PSMA.
Table 2 delineates important targeted delivery approaches that can be used for delivery,
imaging or diagnosis of prostate cancer.

Magnetic nanoparticle based imaging, and detection

Author Manuscript

Early detection is the most vital module for the timely diagnosis of almost all human
cancers, including prostate cancer. This allows uro-oncologists to develop a successful
treatment modality for each individual prostate cancer patient. Detection of cancer cells is
most feasible by choosing exogenous contrast agents. Magnetic resonance imaging (MRI) is
a widely employed imaging tool in medicine that provides a high degree of resolution and
soft tissue contrast without the use of harmful radioisotopes. Typically, SPIONs act as
negative contrast agents (T2 contrast agents or susceptibility agents), because they can
produce hypointense signals of the sample region in T2 and T2*-weighted images, thus
appearing darker. Such a phenomenon is referred to as susceptibility-induced relaxation,
which results from the diffusion of water molecules surrounding the SPIONs through the
large heterogeneity of the magnetic field, leading to relaxation of the protons. This process
provides efficient spin dephasing and transverse relaxation, resulting in decrease in signal
intensity. Gadolinium chelates are FDA-approved MRI T1 contrast agents [69]. However,
their frequent use may lead to toxicity and even tumor formation in patients. Considering
this perspective, recent studies aimed at tailoring SPIONs to offer positive contrast indicated
that increased T1 contrast signals could be achieved [14,70].

Author Manuscript

Various studies have shown a high degree of sensitivity and specificity in identifying benign
and malignant lymph nodes (abdominal and pelvic malignancies) using SPIONs through
MR imaging [71–73]. In addition, SPIONs have been successfully implemented in imaging
bladder cancer [74], ovarian cancer [75], gynecologic malignancy [76], genitourinary tumors
[77], cervical lymph nodes [78], and sentinel lymph nodes for breast cancer [79], etc. In fact,
SPION based formulations that have a marketed status with prescription for various
indications are being used as active ingredients for MRI modality [80]. Molecular Imaging
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and Contrast Agent Database (MICAD) Book [81] recorded at the National Center for
Biotechnology Information (Bethesda, MD, USA) demonstrates that magnetic nanoparticles
as agents were used in animals or human studies. This content exhibits iron oxide
nanoparticles with various single or multi-model dye/radio nucleotides/imaging molecules
including GFP, Cy 5.5, Cy 5.5/FITC, Cy 7, RITC, VT680/64 Cu, and 11ln. These efforts
minimize photobleaching (optical instability) of dyes in physiologically relevant conditions
while reducing the dose and repeated use of imaging agents.

Author Manuscript
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Assembly of probes with desirable properties that combine MRI contrast characteristics with
optical imaging, biological separations, magnetic manipulation, and capture biologically
active molecules has received much attention in the recent past. Magneto-fluorescent
nanoprobes can be achieved by a combination of magnetic nanoparticles and quantum dots
[49]. In this perspective, a combination of two distinct imaging characteristics of iron oxide
nanoparticles and quantum dots can be achieved in a single nanoscale platform for
multimodal imaging [49]. The reason to choose SiQDs over Cd based quantum dots is due to
the fact that it is 10 times safer in biological systems in vitro. This study demonstrated an
improved stability of MSiQD-Mag nanoparticles in the prostate cancer tumor
microenvironment, which can be seen as pseudo-color luminescence signals at the tumor site
spectrally unmixed from autofluorescence in mice even after 24 h post injection. Its
quantitative measurements for stability using emission spectral readings indicate MSiQDMag nanoparticles show superiority both in water and plasma. FITC labeled bombesin
receptor-targeted peptide (FITC-BCDDDGQRLGNQWAVGHLM) conjugated with Cy5.5linked superparamagnetic iron oxide nanoparticle (Cy5.5.-CLIO), which establishes both
MRI contrast and near infrared (NIR) fluorescein imaging modalities [82]. Due to bombesin
peptide, it binds to BN binding receptor on the cells that internalizes ligands and
instantaneously accumulates nanoparticles for sensitive detection.

Author Manuscript

Previous reports demonstrated that a number of factors play a key role in improving
specificity and sensitivity of MRI contrast properties of magnetic nanoparticles. However,
magnetic nanoparticles enhanced MRI detection of lymph node metastases. It is possible
that, in conventional MR imaging, metastases have been missed. A comparative study
indicates that the higher accumulation of intracellular iron in human prostate carcinoma DU
145 cells is indeed reflective in shortening T2 weighed MRI signals in 9.4 T magnet [83]. In
detail, internalized concentration of starch-coated bionized nanoferrite (BNF) (80 pg/cell) >
dextran-coated Johns Hopkins University (JHU) (~45 pg/cell) > Feridex™ (15 pg/cell) >
iron oxide (Nanomag® D-SPIO) (~10 pg/cell), by cancer cells, correlates closely with the
signal intensity of T2-weighted images. A recent study was developed using the one-pot
synthesis approach, which involved iron oxide core and direct encapsulation of amphiphiles
of PEG, DOTA and the PSMA-targeting ligand (glutamate-urea-lysine (GUL) termed as
DOTA-IO-GUL [84]). It demonstrated that there was a dose-dependent binding efficiency in
LNCaP (PSMA+) cells. Both PET and MR imaging results demonstrated selective targeting
and uptake in 22Rv1 (PSMA+), but not PC3 (PSMA−) in tumor xenograft mouse. Aptamers
are a novel class of targeting ligands that can be applied as biological drugs for various
diseases. Bagalkot et al. [85] produced a prostate-specific membrane antigen-specific
aptamer (A10 RNA aptamer) formed by 1:1 physical complex conjugated with doxorubicin
(Dox) through the intercalation approach. This aptamer-Dox conjugate specifically binds to
Drug Discov Today. Author manuscript; available in PMC 2018 August 01.
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PSMA-expressing cells, internalized, and intracellularly delivers doxorubicin in prostate
cancer cells. Additionally, these PSMA aptamer-Dox conjugates are tri-functional, such as
escort molecule (targeting), Dox delivery, and imaging [86]. This behavior was confirmed by
superior targeting using Prussian blue staining, proliferation assay, and MR imaging.

Author Manuscript

PLGA-iron oxide hybrid nanoparticles [23,41] and GoldMag particles (Au/Fe3O4) [87,88]
that have been immobilized or covalently linked with prostate stem cell antigen (PSCA)
antibody exhibit probing capacity of tumors through MR imaging. Magnetic-gold hybrid
nanoparticles carrying fluorescence molecules conjugated with PSMA have shown specific
binding to human prostate cancer cell lines PC3 (PSMA−) and LNCaP (PSMA+) [36]. All
of these findings demonstrate PSMA conjugation benefits both tissue-specific detection/
imaging and therapeutic outcomes [90]. A proof-of-concept study evaluating clinically
relevant detection limits of PSMA (0.05 to 2 pg/mL) can be achieved through magnetic
nanoparticle decorated with anti-PSMA in high-throughput electrochemical microfluidic
immunoarray [89]. According to Table 2 and other related studies, it is important to note that
PSMA ligand tagged formulation can be successfully employed as a multi-/dual-modality
probe for prostate cancer imaging.

Magnetic drug targeting and hyperthermia

Author Manuscript

Magnetic nanoparticle mediated drug targeting is a novel treatment modality to treat prostate
cancer. There is significant evidence that magnetic guided concentration of nanoparticles to
a specified or designated area is feasible under an applied magnetic field. Such an approach
can enhance the local concentration of drug effect. For example, magnetic nanoparticles
with a polyaniline derivative shell exhibited dose dependent cell cytotoxicity in PC3 or
CWR22R cells in a confocal microscopy and proliferation assay [39]. Under a magnetic
field, the increased number of dead cells due to bound PTX was concentrated in a specific
area. This is further reflected in a reduced IC50 (50% cellular growth inhibitions) value
MNPs-PTX applied magnetic field < MNPs-PTX < PTX (4.6 < 9.7 < 11.1 μg/mL in PC3
cells and 1.7 < 4.2 < 7.1 μg/mL in CWR22R cells). Krukemeyer et al. [46] successfully
applied the magnetic targeting principle using extracorporeal 0.6 tesla magnets in adult
Wag/Rij mice, in which higher concentrations of ferromagnetic nanoparticles in tumor
tissues achieved lower systemic concentration, indicating minimal damage of healthy
organs. Tumors treated using this method exhibited fresh necrosis, while the liver and spleen
showed no necrosis. More importantly, no allergies or toxicity concerns were noticed.

Author Manuscript

Magnetic hyperthermia, an upcoming technology of hyperthermia based on applied current
magnetic field (AMF), induced excitation of iron oxide nanoparticles, which produce
localized heat. A PubMed survey (accessed on Decenter 10, 2016) suggests about 150 peerreviewed magnetic hyperthermia articles suggests its possible role of hyperthermia in cancer
therapeutics (https://www.ncbi.nlm.nih.gov/pubmed/?term=magnetic+nanoparticles+and
+hyperthermia). The absolute iron concentration of magnetic nanoparticles correlates with
the hyperthermia potential [83]. Magnetic nanoparticles can be efficiently internalized
intracellularly via differential endocytosis pathways, offering the perspective hyperthermia
potential. The absolute iron concentration of magnetic nanoparticles correlates with the
hyperthermia potential [83]. Various rat models of prostate cancer indicated not only
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feasibility and good tolerability of magnetic hyperthermia, but also significant local
hyperthermic effects in reducing tumor burden. Physicochemical properties of the iron oxide
nanoformulation play a critical role in the ability to generate heat. For example, although the
surfactants used to stabilize the iron oxide nanoparticles do alter in their overall size of
nanoformulation, the amount of surfactant drastically decreases heating capacity (Sodium
citrate 0–30 mM changes SAR from ~ 100 to 20 W/g; oleic acid 0–30 mM changes SAR
from ~ 100 to 38 W/g) [92].

Author Manuscript

Magnetic nanoparticle mediated delivery of 5-FU is much more prominent with 2 Gy X-ray
treatment in DU 145 prostate cancer cells [22]. A recent study demonstrates that upon
treatment with 5.5 mgFe/cm3 tumor in LAPC4 and PC3, xenograft nude mice tumors yield
statistically significant tumor growth delay when applied to variable AMF peak amplitude
with 5 Gy radiation compared with a fixed thermal dose or radiation. [93]. Similarly,
magnetic hyperthermia helps to sensitize PC3/LAPC4 tumors in athymic BALB/c nu/nu
mice for radiation treatment [86]. In an Orthotopic Dunning R3327 Rat Model [94] study,
magnetic hyperthermia could reduce tumor burden while only 5.3, 1.0, and 0.5% of the
injected magnetic nanoparticle dose was found in the liver, lung, and spleen, respectively.
All of these investigations indicate positive therapeutic outcomes of magnetic hyperthermia
for prostate cancer. Magnetic cationic liposomes show excellent therapeutic outcomes in
conjunction with AMF heat therapy in calvaria F344 male rats [31]. This combination
therapy suppressed tumor growth in the bone microenvironment, which may be useful for
bone metastatic prostate tumors.

Author Manuscript

NanoTherm™ therapy was developed by MagForce AG (a Germany based company, http://
www.magforce.de/en/produkte/nanothermr-therapie.html), which is an advanced treatment
modality of magnetic hyperthermia for the local treatment of solid tumors. This therapy uses
~15 nm in diameter aminosilane-coated iron oxide nanoparticles (Nanotherm®) and a
magnetic field activator (NanoActivator®) that changes its polarity up to 100,000 times per
second, generating heat. Such therapy outcomes are positive in glioblastoma multiforme,
prostate, esophageal, and pancreatic cancers. MagForce has taken an initial step, has some
early, yet encouraging, research results in glioblastoma trials, and intends to examine some
studies in the USA. However, magnetic hyperthermia technology is still undergoing
investigational studies and is not readily available for clinical use.

Concluding remarks and future perspective

Author Manuscript

This review article summarizes magnetic nanoparticles, which can be modified and
established for superior biocompatibility, magnetic resonance imaging characteristic and
targeted delivery of payloads. Such modified magnetic nanoparticles are attractive and
potentially well suitable for theranostic applications in prostate cancer. More importantly,
these theranostic nanoformulations would enable monitoring of disease progression while
undergoing treatment, implied as see-and-treat technology. However, the scope of magnetic
nanoparticles is still mainly limited to imaging purposes and has not yet been implemented
as a therapeutic module, which needs to occur.
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In this regard, magnetic nanocarriers need to be modified with targeting ligands that can
specifically bind to prostate cancer-specific antigens. Moreover, there are several specific
enzymes in the tumor microenvironment of prostate cancer that can be exploited for
stimulus-responsive therapeutic system(s). These systems can specifically release the active
drug in the tumor microenvironment of prostate cancer, leading to enhanced tumor
penetration efficiency. Moreover, developing a magnetic nanoparticle formulation with a
chemosensitizer along with a main clinical drug would improve chances of applicability in
clinical settings. Magnetic hyperthermia would also be beneficial to improve both chemo
and radiation therapies. However, it shows some regional toxicity.

Author Manuscript

A number of investigations dealing with the monoclonal antibody conjugated to the surface
of magnetic nanoparticles have been tested in both in vitro and in vivo milieus. Most of
these formulations exhibited substantial targeting in in vitro prostate cancer cell line models.
However, from the accumulated data it appeared that due to the formation of additional
coating development on magnetic nanoparticles by the protein corona in in vivo conditions,
they were unable to detect the targeting site efficiently, resulting in poor in vivo targeting
profile. Such formulations may end up residing in the liver and spleen due to extensive
absorption of the opsonin proteins on the surface of particles. These drawbacks compromise
not only the imaging agent potential for detecting, but also the monitoring of prostate cancer
response during treatment regimens. Therefore, there is a strong possibility that generation
of stable and targeted magnetic nanoparticle formulations may resolve these issues. In order
to use magnetic nanoparticle formulations as a clinical therapeutic weapon to fight against
prostate cancer, there must be a facile preparative approach, high reproducibility and
stability, and greater accumulation at the tumor site.
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Highlights
•

Magnetic nanoparticles with multi-functionality can used for theranostic
applications

•

Various magnetic nanoparticle mediated therapeutic strategies are
summarized.

•

Magnetic hyperthermia and targeting is an alternative strategy to treat prostate
cancer

•

Targeted magnetic nanoparticles delivery of therapeutics is still warranted
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Teaser
This review article highlights the current state of the magnetic nanoparticle technologies
for prostate cancer. A detailed recent advances in research and development of magnetic
nanoparticles for theranostic application.
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Figure 1.

Use of magnetic nanoparticles in various materials science and biomedical research
applications. A) Use of magnetic nanoparticles in therapy, diagnosis (in vitro, in vivo, and
pre-clinical) and other nanotechnology research areas. B-C) Peer-reviewed articles published
in PubMed until December 15, 2016.
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Role of surface coating and therapeutic effects of chemotherapeutic agents with magnetic nanoparticle
mediated delivery
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Coating

Drug

Physicochemical characterization

Utilization

Anionic glycosaminoglycan [37]

Doxorubicin

11 nm particle size
-39 mV zeta potential

Enhanced tumor-cell
internalization and tumor uptake in
R3327 AT1 rat tumors.

Serum albumin [24]

Doxorubicin

210 nm particle size
2.5 emu/g magnetic saturation (Ms)

Doxorubicin pharmacodynamic
property retained upon loading in
BSA coated MNPs. DOX-BSANPs exhibits superior inhibition
effect against PC3 and A549 cells
over DOX. IC50 values of DOX
and DOX-BSA-NPs were 0.14 and
0.51 μM (PC3 cells), and 3.24 and
9.13 μM (A549 cells).

PNIPAAm-AAm-AH
thermosensitive polymer coated
nanoparticles [35]

Doxorubicin

~100 nm particle size
~2% DOX loading

6-fold increase of doxorubicin
release at 41°C over 37°C and 4°C.

Oleic acid – Pluronic® F127 [29]

Doxorubicin

193 nm particle size with a polydispersity
index of 0.262 (TEM size data was 11 ± 2
nm)
88.8 ± 0.5 emu/g MS

DOX-loaded MNPs exhibited a
dose-dependent cytotoxicity on
MCF-7 and PC3 cells. Due to slow
release DOX-loaded MNPs
demonstrated slightly lower effects
than DOX in solution

1-octadecylamine and DSPE-PEG
[38]

Paclitaxel

29 ± 2 nm particle size
247 ± 33 μg/mL of platinum loading
Transverse relaxivities of r2 = 300 ± 12 and
389 ± 16 Hz/mM iron

PSMA-targeted J591-SPMs bound
specifically to C4-2 cells. The data
show that only the J591-SPMs and
paclitaxel were able to prevent
growth of tumors in the mice
significantly.

polyaniline derivative doped
nanoparticles [39]

Paclitaxel

73.7 nm particle size
−30.5 ± 0.45 mV zeta potential
53.2 emu/g MS

Bound-PTX MNPs were more
toxic to PC3 and CWR22R cells.
The IC50 value of bound-PTX
MNPs was 9.7 μg/mL (free PTX,
11.1 μg/mL) and 4.2 μg/mL (freePTX, 7.1 μg/mL) in PC3 and
CWR22R cells, respectively.
(specify R as resistance cells)

PLGA-iron oxide [40]

Radio-sensitizer
8dibenzothiophen4-yl-2morpholin-4-ylchromen-4-one
(NU7441)

260 nm particle size
48.64 emu/g MS
Bi-phasic release of NU7441: 41% (a day)
and 90.48% (for 3 weeks)

NU7441 PLGA-MNPs were more
effective in H460 and PC3 cells.

PLGA Poly(allylamine
hydrochloride) PEG [41]

Docetaxel

187.4 ± 32.7 nm particle size Cumulative
release 75.9% for scAb-PLGA-SPIO/
docetaxel

The IC50 of scAb-PLGA-SPIO/
docetaxel formulation was
demonstrated to be 1.38, 1.68, and
1.95-fold lower than those for
unconjugated docetaxel
nanoformulation at 24, 48, and 72
hrs in PC3M cells.

Carboxy-terminated PLGA [23]

Docetaxel

124.5 ± 10.2 nm and 146.9 ± 8.6 nm
particle size 60.5 emu/g and 23.3 emu/g MS
before and after modification

Improved cellular internalization
ability and thus induces superior
anti-proliferative activity in PC3
cells, confirmed by confocal laser
scanning microscopy and
proliferation assays.

Ethylene glycol composite [42]

Bicalutamide

20 nm particle size

A basic study indicating
bicalutamide loaded composite
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Coating

Drug

Physicochemical characterization

Utilization
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MNPs were cytotoxic to DU145
cells.
Pluronic® L-121 [27]

Camptothecin

Polymersomes were coated on to 10 nm
MNP core nanoparticles

This formulation demonstrated
higher signal amplitudes with
respective to iron content in
magnetic particle spectroscopy
compared to Endorem® and
Feraheme®.

Citrate-octanoic acid coated
nanoparticles [43]

Zoledronate

10 nm particle size with polydispersity of
20%

The γFe2O3@Zoledronate
formulation promotes inhibitory
effect due to nanocrystal cell
internalization.
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Table 2
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Role of magnetic nanoparticles in specific targeting, imaging and detection of prostate cancer
Formulation/Composition

Linker /conjugation process

Targeting ligand

Outcome

Imaging modality

Oleic acid-coated IO NPs
DOTA Polysorbate 60

Physical absorption on the surface of
NPs

GUL

Cellular uptake in
LNCaP cells a
specific targeting in
22Rv1 mouse
xenografts.

MRI and PET [84]

Iron oxide core nanoparticles
with CdSe QDs, PEG
derivatives

Conjugation at the distal ends of
lipid-PEG derivative

cRGDyk peptide

Stable and effective
detection signals
with low systemic
toxicity and mainly
accumulates in
tumors and liver.

MRI and
fluorescence [59]

Significant cellular
uptake stable
luminescence in
prostate cancer
tumor model.

Luminescence [49]

Silicon quantum dots and
SPIONs with phospholipid-PEG
micelles

Author Manuscript
Author Manuscript
Author Manuscript

SPION with PEG

Biotinylated phospholipids

PSMA

SPIONs with PSMA
MAb targets
efficiently C4-2
xenograft tumors in
mice and
specifically directs
the drug to the
tumors, thus
prevents tumor
growth. Further, it
showed good
transverse
relaxivities of 389
± 15.5 Hz/mM
(MRI contrast
enhancement in
vivo) with this
formulation

MRI [38]

oleic acid-capped nanoparticles

N-hydroxysuccinimide/N-(3dimethylaminopropyl)-N′ethylcarbodiimide hydrochloride
near-infrared fluorescence probe
1,1′-dioctadecyl-3,3,3′,3′tetramethyl indotricarbocyanine
iodide (DIR)

PSMA

A proof-of-concept
study demonstrates
conjugation with
PSMA-targeting
antibody, J591, and
demonstrated
enhanced MRI
potential in a
preclinical model of
orthotopic prostate
cancer xenografts in
mice.

MRI and
Fluorescence [90]

PLGA composite iron oxide
nanoparticles

α-maleinimido-omega-carboxy PEG

PSCA

Due to PSCA
conjugation
significant cellular
uptake of
formulation was
found which is
evident from their
T2- weighted
images (comparable
or slightly better
than of the
Endorem® at the
same concentration
of Fe concentration)
in PC3 cells.

MRI and
fluorescence [23]
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Formulation/Composition

Linker /conjugation process

Targeting ligand

Outcome

Imaging modality

SPIONs

Direct attachment/binding

Chlorotoxin
tumor cellspecific peptide

A proof-of-concept
nanoparticle probe
with magnetic
nanoparticles with
chlorotoxin peptide
exhibits substantial
targetability and
accumulation in
cancer cells and thus
inhibits invasiveness
of cells (98%).

[57].

SPIONs

No agent

EPR effect

This is an early
attempted study
demonstrating
ability to detect
nodal metastases,
and a node-by-node
analysis with
significantly higher
sensitivity than
conventional MRI.

MRI [91]
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